ATV 40 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Atorvastatin calcium |
| Company | Delta pharma ltd |
| Also available as |
Title
ATV 40 mg Tablet
Categories
- Medicine
- Cholesterol
- Cardiovascular Health
Description
ATV 40 mg Tablet is a selective inhibitor of HMG-CoA reductase. It is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B) and triglycerides levels in several diseases. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver, and increases the number of hepatic LDL receptors for enhanced uptake and catabolism of LDL.
Dimensions
- Tablet size: 40 mg
- Dosage form: Tablet
Color options
- White
Functions
- Reduces total cholesterol and LDL cholesterol levels
- Lowers apolipoprotein B (Apo-B) and triglycerides levels
- Prevents cardiovascular events
- Treats hypercholesterolemia associated with diabetes mellitus or renal transplantation
Materials
- Atorvastatin
Technical specifications
- Absorption: Rapidly absorbed after oral administration with maximum plasma concentrations occurring within 1 to 2 hours
- Bioavailability: Approximately 14%
- Distribution: Mean volume of distribution is approximately 381 liters
- Protein binding: 98%
- Metabolism: Extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products
- Half life: Approximately 14 hours
Usability features
- Dosage administration:
- Usually 10 mg once daily; may be increased at intervals of at least 4 weeks to max. 80 mg once daily for adults
- Initial dose for children (10-18 years) is 10 mg once daily, increased if necessary to usual max. 20 mg once daily
- Storage conditions: Keep in a dry place away from light and heat, and out of the reach of children
- Precautions warnings: Liver function tests should be performed before initiation of treatment and periodically thereafter; ATV therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected
Design elements
- Chemical structure - C33H35FN2O5
Side effects
- Constipation
- Flatulence
- Dyspepsia
- Abdominal pain
- Infection
- Headache
- Back pain
- Rash
- Asthenia
- Arthralgia
- Myalgia
Precautions warnings
Liver function tests should be performed before the initiation of treatment and periodically thereafter. ATV should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. ATV therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.
Dosage administration
- Adults: Usually 10 mg once daily; may be increased at intervals of at least 4 weeks to max. 80 mg once daily
- Children: Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily
Interactions
- Cyclosporine
- Fibric acid derivatives
- Niacin (nicotinic acid)
- Erythromycin
- Azole antifungals
- Antacid
- Colestipol
- Digoxin
- Oral Contraceptives
- Warfarin
Contraindications
- Hypersensitivity to any component of this medication
- Active liver disease or unexplained persistent elevations of serum transaminases
- History of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors
Pregnancy lactation
- Pregnancy: Atorvastatin is contraindicated during pregnancy; safety in pregnant women has not been established
- Lactation: It is not known whether atorvastatin or its metabolites are excreted in human milk; atorvastatin is contraindicated during breastfeeding
Special populations
- Geriatric: Plasma concentrations of ATV are higher in healthy elderly subjects (age 65 years) than in young adults
- Pediatric: Pharmacokinetic data in the pediatric population are not available
- Gender: No clinically significant difference in LDL-C reduction between men and women
- Renal insufficiency: Renal disease has no influence on the plasma concentrations or LDL-C reduction of ATV
- Hemodialysis: Not expected to significantly enhance clearance of ATV
- Hepatic insufficiency: In patients with chronic alcoholic liver disease, plasma concentrations of ATV are markedly increased
Overdose effects
Specific treatment is not available for atorvastatin overdose; the patient should be treated symptomatically and supportive measures instituted, as required
Therapeutic class
- Other Anti-anginal & Anti-ischaemic drugs
- Statins
Storage conditions
Keep in a dry place away from light and heat, and out of the reach of children